NCT00041093

Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer

A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Gynecologic Oncology Group · Network
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

Phase II trial to study the effectiveness of docetaxel in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Detailed description

PRIMARY OBJECTIVES: I. Determine the antitumor activity of docetaxel in patients with persistent or recurrent squamous cell carcinoma of the cervix. II. Determine the toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Conditions

• Cervical Squamous Cell Carcinoma, Not Otherwise Specified
• Recurrent Cervical Carcinoma

Interventions

Type	Name	Description
DRUG	Docetaxel	Given IV

Timeline

• Start date: 2002-06-01
• Primary completion: 2006-10-23
• First posted: 2003-01-27
• Last updated: 2018-01-10

Locations

1 site across 1 country: United States